Faculty Opinions recommendation of Screening of small molecule interactor library by using in-cell NMR spectroscopy (SMILI-NMR).

Author(s):  
Peter Wipf ◽  
Marie-Céline Frantz
2018 ◽  
Vol 54 (96) ◽  
pp. 13507-13510 ◽  
Author(s):  
Kumar Motiram-Corral ◽  
Míriam Pérez-Trujillo ◽  
Pau Nolis ◽  
Teodor Parella

The concept of multiple-FID acquisition (MFA) within the same scan is applied to acquire simultaneously multiple 2D spectra from a single NMR experiment. A discussion on the incorporation of the MFA strategy in homonuclear and heteronuclear pulse sequences is presented. Several novel COSY- and HMBC-type experiments are reported as a time-efficient solution in small-molecule NMR spectroscopy.


2011 ◽  
Vol 77 (5) ◽  
pp. 301-308 ◽  
Author(s):  
Christiane Riedinger ◽  
Martin E. Noble ◽  
David J. Wright ◽  
Florian Mulks ◽  
Ian R. Hardcastle ◽  
...  

2021 ◽  
Author(s):  
James D Vasta ◽  
D. Matthew Peacock ◽  
Qinheng Zheng ◽  
Joel A Walker ◽  
Ziyang Zhang ◽  
...  

Current small molecule inhibitors of KRAS (G12C) bind irreversibly in the switch-II pocket, exploiting the strong nucleophilicity of the acquired cysteine as well as the preponderance of the GDP-bound form of this mutant. Nevertheless, many oncogenic KRAS mutants lack these two features, and it remains unknown whether targeting the switch-II pocket is a practical therapeutic approach for KRAS mutants beyond G12C. Here we use NMR spectroscopy and a novel cellular KRAS engagement assay to address this question by examining a collection of SII-P ligands from the literature and from our own laboratory. We show that the switch-II pockets of many GTP hydrolysis-deficient KRAS hotspot (G12, G13, Q61) mutants are accessible using non-covalent ligands, and that this accessibility is not necessarily coupled to the GDP state of KRAS. The results we describe here emphasize the switch-II pocket as a privileged drug binding site on KRAS and unveil new therapeutic opportunities in RAS-driven cancer.


2009 ◽  
Vol 52 (11) ◽  
pp. 3516-3522 ◽  
Author(s):  
Jingjing Xie ◽  
Rajiv Thapa ◽  
Sergey Reverdatto ◽  
David S. Burz ◽  
Alexander Shekhtman

2020 ◽  
Author(s):  
Donald Gagné ◽  
Roksana Azad ◽  
Uthama R. Edupuganti ◽  
Justin Williams ◽  
James M. Aramini ◽  
...  

AbstractSmall molecule binding within internal cavities provides a way to control protein function and structure, as exhibited in numerous natural and artificial settings. Unfortunately, most ways to identify suitable cavities require high-resolution structures a priori and may miss potential cryptic sites. Here we address this limitation via high-pressure solution NMR spectroscopy, taking advantage of the distinctive nonlinear pressure-induced chemical shift changes observed in proteins containing internal cavities and voids. We developed a method to rapidly characterize such nonlinearity among backbone 1H and 15N amide signals without needing to have sequence-specific chemical shift assignments, taking advantage of routinely available 15N-labeled samples, instrumentation, and 2D 1H/15N HSQC experiments. From such data, we find a strong correlation in the site-to-site variability in such nonlinearity with the total void volume within proteins, providing insights useful for prioritizing domains for ligand binding and indicating mode-of-action among such protein/ligand systems. We suggest that this approach provides a rapid and useful way to rapidly assess otherwise hidden dynamic architectures of protein that reflect fundamental properties associated with ligand binding and control.Significance StatementMany proteins can be regulated by internally binding small molecule ligands, but it is often not clear a priori which proteins are controllable in such a way. Here we describe a rapid method to address this challenge, using solution NMR spectroscopy to monitor the response of proteins to the application of high pressure. While the locations of NMR signals from most proteins respond to high pressure with linear chemical shift changes, proteins containing internal cavities that can bind small molecule ligands respond with easily identified non-linear changes. We demonstrate this approach on several proteins and protein/ligand complexes, suggesting that it has general utility.


Synthesis ◽  
2021 ◽  
Author(s):  
Jacob St-Gelais ◽  
Denis Giguère

Small-molecule galectin inhibitors are useful research tools that could also be used as potential drug candidates. In that context, GB1107, a monosaccharidic galectin inhibitor, was shown to be an orally active galectin-3 antagonist that inhibits lung adenocarcinoma growth. Herein, we describe a protecting-group-free synthesis of GB1107, along with other analogues. Starting from inexpensive levoglucosan, we used a Payne rearrangement/azidation process as key step. Finally, we explored the use of a log P determination method based on 19F NMR spectroscopy to assess the lipophilicity of galectin inhibitors.


Sign in / Sign up

Export Citation Format

Share Document